Tạp chí Tim mạch học Việt Nam

Article detail

Article detail description

Home
NGHIÊN CỨU LÂM SÀNG Issue: Số 68 (2014) BỆNH SUY TIM

No translate

Published: October 31, 2014
Views: 458

Abstract

Background and basis: Currently, there is no specific treatment option for the pulmonary hypertensive complication in patients with chronic left heart failure. Many studies have shown that prolonged use of sildenafil can reduce pulmonary artery pressure in this patient population. Subjects and Methods: 61 patients with chronic left heart failure with pulmonary hypertension, receiving medical treatment according to the standard therapy, were randomized into 2 groups: the sildenafil group (sildenafil was added, average dose of 50 mg/day) and the control group (no sildenafil). Results: After 4 weeks of treatment, the rate of NYHA IV, Minnesota quality of life score, 6-minute walk distance and mean pulmonary artery pressure (mPAP) of the sildenafil group significantly improved from baseline (-15%, -19, +11 m, -9 mmHg, respectively, p<0.01), and significantly improved compared to the control group (-15% vs -9%, -19 vs -10, +11 m vs +7 m, -9 mmHg vs -2 mmHg, respectively, p<0.01). Conclusions: Sildenafil was well tolerated; it may be an appropriate treatment option for patients with left heart failure who develop secondary pulmonary hypertension.

Keywords
sildenafil pulmonary hypertension chronic left heart failure treatment

References

1.
1. Butler J, Chomsky DB, Wilson JR. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol. 1999; 34: 1802-1806.
2.
2. Guazzi M, Samaja M, Arena R. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007 Nov 27;50(22):2136-44. Epub 2007 Nov 13.
3.
3. Gregory D. Lewis, MD; Ravi Shah, MD. Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension. Circulation. 2007; 116: 1555-
4.
4. erald Roul, MD, Philippe Germain, MD. Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure? Am Heart J 1998; 136:449-57.)
5.
5. Guazzi M, Tumminello G, Di Marco F. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol. 2004 Dec 21;44(12):2339-48.
6.
6. Cvelich RG, Roberts SC, Brown JN. Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure. Ann Pharmacother. 2011 Dec; 45 (12) : 1551-8.
7.
7. Arnon Blum MD. Treating Heart Failure With Sildenafil. Congestive Heart Failure. Volume 15, Issue 4, 181-185, July/August 2009.
8.
8. Cèsar Morcillo, Ofelia Aguado. Utility of the Minnesota Living With Heart Failure Questionnaire for Assessing Quality of Life in Heart Failure Patients. Rev Esp Cardiol. 2007; 60:1093-6.- Vol. 60 Num.10.
9.
9. Behlouli H, Feldman DE. Identifying relative cut-off scores with neural networks for interpretation of the Minnesota Living with Heart Failure questionnaire. Conf Proc IEEE Eng Med Biol Soc. 2009;2009:6242-6.

Tác giả

Trần Lâm: Bệnh viện Đa khoa Quảng Nam;
No translate

Files

Article Views458
Document Views0
Downloads22
Section NGHIÊN CỨU LÂM SÀNG
Category BỆNH SUY TIM
Pages 250-256
Copyright Holder 2014 Tạp chí Tim mạch học Việt Nam